4 active not recruiting, 1 completed, 1 recruiting, 1 suspended. 5 Phase 1, 4 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 2 | 4 | Active not recruiting 4 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Metastatic Soft-tissue Sarcoma: new trials by email Literature Review of Metastatic Soft-tissue Sarcoma trials Research Report on Metastatic Soft-tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma Zanzalintinib, Ipilimumab, Nivolumab - Metastatic Soft-tissue Sarcoma | Phase 1 | Suspended | Washington University School of Medicine | 18 | 2026-01-05 | 2026-09-04 |
| T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy - Metastatic Soft-tissue Sarcoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2025-09-29 | 2026-08-18 |
| Gemcitabine With Ascorbate Including Adolescents Ascorbate, Gemcitabine - Soft Tissue Sarcoma, Bone Sarcoma | Early Phase 1 | Withdrawn | David Dickens | 2023-01-01 | 2023-02-22 | |
| HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas Pazopanib, HDM201 - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Centre Leon Berard | 47 | 2022-04-15 | 2026-06-22 |
| Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma Bintrafusp alfa, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 2 | Active not recruiting | Institut Bergonié | 80 | 2022-03-01 | 2026-07-24 |
| A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma NOX66, Doxorubicin - Metastatic Soft-tissue Sarcoma | Phase 1 | Terminated | Noxopharm Limited | 9 | 2022-02-11 | 2025-01-06 |
| Lurbinectedin + Doxorubicin In Leiomyosarcoma Lurbinectedin, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Massachusetts General Hospital | 62 | 2022-02-04 | 2026-08-27 |
| Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients Doxorubicin, Cyclophosphamide - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 3 | Unknown | UNICANCER | 214 | 2021-06-18 | 2025-03-25 |
| Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma Cabozantinib, Nivolumab, Ipilimumab - Metastatic Soft-tissue Sarcoma | Phase 2 | Active not recruiting | Washington University School of Medicine | 105 | 2021-01-05 | 2025-11-12 |
| Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS) No Intervention - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Completed | GWT-TUD GmbH | 72 | 2017-02-02 | 2022-04-04 |
Sarcoma (10) · Bone Neoplasms (1) · Neoplasm Metastasis (1) · Tertiary Lymphoid Structures (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Connective and Soft Tissue (10) · Bone Diseases (1) · Musculoskeletal Diseases (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
Doxorubicin (4) · Cyclophosphamide (2) · Ipilimumab (2) · Nivolumab (2) · Ascorbic Acid (1) · Gemcitabine (1) · PM 01183 (1) · bintrafusp alfa protein, human (1) · cabozantinib (1) · pazopanib (1) · siremadlin (1)
Washington University School of Medicine (2) · Centre Leon Berard (1) · David Dickens (1) · GWT-TUD GmbH (1) · Institut Bergonié (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Noxopharm Limited (1) · UNICANCER (1)
United States (6) · France (3) · Austria (1) · Germany (1) · Switzerland (1)
Mia Weiss, M.D. (2) · Bernd Kasper, Prof. (1) · David Dickens, MD, FAAP (1) · Gregory Cote, M.D. Ph.D (1) · Neeta Somaiah, MBBS (1) · Olivier Mir, M.D (1) · Thibaud Valentin, M.D (1)
2018 (1)